Efficacy analysis of 125I seeds implantation combined with transcatheter arterial chemoembolization therapy for primary liver cancer
10.3760/cma.j.cn321828-20221114-00343
- VernacularTitle:125I粒子植入联合肝动脉灌注化疗栓塞治疗原发性肝癌的疗效分析
- Author:
Wenwen ZHANG
1
;
Shanhu HAO
;
Zhiguo WANG
;
Liqiu JI
;
Gen LI
;
Youchao WANG
;
Xiangyan GE
;
Guoxu ZHANG
Author Information
1. 北部战区总医院核医学科，沈阳 110016
- Keywords:
Liver neoplasms;
Brachytherapy;
Iodine radioisotopes;
Chemoembolization, therapeutic;
Hepatic artery;
Treatment outcome
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2024;44(1):16-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy of 125I seeds implantation combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods:A retrospective analysis of data from 40 patients with primary liver cancer at the Northern Theater General Hospital from January 2018 to December 2020 (26 males, 14 females, age 41 to 82 years) was performed. Among them, 21 patients were in treatment group and underwent 125I seeds implantation combined with TACE treatment, while 19 patients were in control group and received TACE treatment. Alpha-fetoprotein (AFP) levels between the two groups were compared, effective rate and disease control rate (DCR) of the two groups were analyzed, and overall survival (OS) and progression-free survival (PFS) were observed. Data were analyzed by using Mann-Whitney U test, χ2 test, Kaplan-Meier method and log-rank test. Results:Two months after 125I seeds implantation, the effective rates of treatment group and control group were 76.19%(16/21) and 8/19, respectively ( χ2=4.83, P=0.028); the DCRs were 90.48%(19/21) and 11/19, respectively ( χ2=4.21, P=0.040). AFP levels in both groups decreased significantly, with treatment group showing a greater decrease rate (0.87(0.84, 0.90) and 0.66(0.65, 0.67); z=5.42, P<0.001). No serious adverse reaction was observed in either group. The median OS of treatment group and control group were 18.2 and 10.6 months, respectively ( χ2=10.98, P=0.037); the median PFS of the two groups were 8.4 and 6.1 months, respectively ( χ2=7.54, P=0.041). Conclusion:125I seeds implantation combined with TACE treatment can exert a synergistic and enhancing effect in the treatment of primary liver cancer.
